cerrar
Tagged with Pricing

EUnetHTA’s Uncertain Future & the Evolution of…
The journey of EUnetHTA began back in 2004, when the European Commission and Council of Minsters requested the establishment of a sustainable European…

Five Trends for Life Science Companies to Watch in 2021
After a transformative 2020, Shawview Consulting’s Brendan Shaw looks into his crystal ball and makes five predictions (plus one) on the key trends…

Niklas Hedberg – Chair of the Executive Board, EUnetHTA;…
Niklas Hedberg outlines the role of EUnetHTA as both a network and project built up of national HTAs in Europe, the potential for a continent-wide…

Cross Country Collaborations in Europe: The Future of Pricing…
Merck VP for Global Market Access & Pricing Strategic Planning Marco Rauland examines the trend of collaboration between European countries…

Novartis Oncology President: “If We Offer Pay-For-Performance,…
During the FT Global Pharmaceutical and Biotechnology Conference earlier this month, three industry leaders spoke about innovative reimbursement…

Marcel Plattner – President, vips, Switzerland
Marcel Plattner, president of Swiss industry association vips discusses pricing, market access and innovation, as well as the continuing…

Axel B Müller – Managing Director, Intergenerika,…
Intergenerika’s Dr Axel B. Müller makes an impassioned case against the introduction of a reference pricing system in Switzerland, arguing that it…

Paying for Cell & Gene Therapy in the USA: Is the Future…
Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced, the multiple models now under…

Has the Time Truly Come for Trudeau’s ‘National Pharmacare’…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the…

Market Access in Switzerland: Reimbursement Delays for 76% of New…
Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to…

US Elections: Biden & Trump’s Unworkable Drug Pricing…
In the aftermath of the fiery first presidential debate between incumbent Donald Trump and Democratic Party rival Joe Biden, we round up the latest on…

This Could Get Messy: Trump’s New ‘Most Favoured Nation’…
Regular PharmaBoardroom contributor Brendan Shaw weighs in on the potential implications for US pharma of President Donald Trump’s latest executive…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here